Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New hospital purchasing guidelines in Germany could force medtech companies to rethink traditional strategies

This article was originally published in Clinica

Executive Summary

The German market for medical devices is by no means as open to innovation as it was a few years ago. The criteria for paying for treatment by health insurers have been expanded to include cost-efficiency although the evaluation formulae have not yet been established. But, say consultants Hans-Jurgen Wildau and Bernd Grohs, potentially expensive outlays for developing innovative medical products can be reduced by integrating partners from different healthcare sectors early on.

You may also be interested in...



Mylan Bids To Win EU Approval For Upjohn Merger

Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.

IGBA Criticizes Export Restrictions

National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.

Italy’s Dompé Taking Legal Action Over COVID-19 Fake News

Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.

Topics

UsernamePublicRestriction

Register

MT081660

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel